ASH 2010 Conference Coverage

Statins may lower progression risk for renal cancer

Use of statins is associated with a reduced risk of progression of localized renal cell carcinoma, according to research.

Cyramza approved by FDA for stomach cancer

Cyramza (ramucirumab) has been approved by the U.S. Food and Drug Administration to treat cancer of the stomach.

Genes may predict the need for further cancer treatments

A new predictive tool is being developed that could help patients with breast cancer and certain lung cancers decide whether follow-up treatments are likely to help.

Early promise from therapy targeting FGFR mutations

The investigational drug BGJ398 showed promising anticancer activity in patients with various types of cancer driven by FGFR genetic alterations.

New immunotherapy promising for advanced melanoma

A new type of immunotherapy that directs patients' immune responses toward tumor cell killing, IMCgp100, showed efficacy in some patients with advanced melanoma.

Cancer patients require anxiety and depression screening

It is important to recognize and treat anxiety or depression among cancer patients, according to a clinical guideline published in the Journal of Clinical Oncology.

More awareness of sexual dysfunction in lung cancer patients is needed

Many lung cancer patients experience difficulties with sexual expression and intimacy, a topic that has long been ignored by doctors and researchers.

Pain management in patients with low BP

When a patient's blood pressure is low, pain medications are often withheld. How is this situation best managed?

Epigenetic therapy clinically active against several blood cancers

Patients with a variety of hematologic cancers benefited from treatment with OTX015, a member of a new class of investigational epigenetic therapies that block the activity of bromodomain and extraterminal (BET)-bromodomain proteins.

Cause of resistance to PI3K-alpha inhibitor identified

In women with breast cancer, loss of the tumor suppressor PTEN was a frequent cause of resistance to the investigational drug BYL719, which blocks the activity of a protein called PI3K-alpha.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs